



0957-4166(94)00143-X

Biocatalytic Resolution of β -Fluoroalkyl- β -Amino Acids

Vadim A. Soloshonok*¹

Catalysis Research Center and Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060, Japan

Alexander G. Kirilenko, Nataly A. Fokina, Irine P. Shishkina, Sergey V. Galushko,
and Valery P. Kukhar

Institute of Bioorganic Chemistry and Petrochemistry, Ukrainian Academy of Sciences, Kiev 253160, Ukraine

Vytas K. Švedas* and Elena V. Kozlova


A. N. Belozersky Institute of Physical-Chemical Biology, Moscow State University, Moscow 119899, Russia

Abstract: *N*-Phenylacetyl derivatives of β -fluoroalkyl- β -alanines **6** were synthesized and biocatalytically resolved to the corresponding enantiopure β -amino acids **7**, **9** with the aid of penicillin acylase (EC 3.5.1.11) from *Escherichia coli*. In substrates **6** the enantioselectivity of the biocatalytic process was practically uninfluenced by the nature of the fluoroalkyl chain. Thus, β -fluoroalkyl- β -alanines **7**, **9** bearing short (R = CF₃, CHF₂) or long [C₃F₇, H(CF₂)₄] chains were prepared in high enantiomeric purity. The (*R*)-enantiomer was the fast-reacting enantiomer in all cases.

Introduction.

In recent decades, organofluorine chemistry has made a marked impact on the design and synthesis of many kinds of biologically active molecules such as steroids, carbohydrates, amino acids, peptides, and other natural products.² The progress in fluorine-containing amino acid chemistry has revealed that this type of unnatural amino acids, especially those which are CF₃ branched or possess fluorine atom(s) in the β -position to amino group, are highly biologically active molecules with a wide range of potential applications.³ However, most of the research in the field has been focused on the chemistry of fluorinated α -amino acids. Conversely, there are relatively few methods for the synthesis of optically pure fluorine-containing β -amino acids.³ To our knowledge, only one type, namely, α -fluoro- β -amino acids are potentially available in optically active form by the Welch chemistry.⁴ On the other hand, in recent years, there has been a substantial interest in the synthesis of β -amino acids. Thus, being important constituents of many classes of natural products,⁵ β -amino acids attract considerable interest as useful chiral structural units for the synthesis of compounds of pharmaceutical interest.⁶ In view of beneficial medicinal effects that fluorine can impart to biologically active molecules the importance of fluorine-containing β -amino acids as a potentially biologically active compounds became clear. Our strategy on this project involves a two-pronged approach which includes asymmetric synthesis⁷ and biocatalytic resolution⁸ of racemates. In this paper we report a convenient method for the preparation of β -fluoroalkyl- β -amino acids in optically pure form *via* resolution of their racemic *N*-phenylacetyl derivatives by means of penicillin acylase (EC 3.5.1.11) from *Escherichia coli*.

Scheme 1



Reagents and Conditions: *i*, benzene or toluene, Dowex-50 or *p*-Tol-SO₃H, reflux; *ii*, base (NEt₃ or 1,8-diazabicyclo[5.4.0]undec-7-ene); *iii*, 2 N HCl, room temperature, 2 hr.; *iv*, 6 N HCl, 90 °C, 6 hr.; *v*, Dowex-50, 0.2 N NH₄OH


Results and Discussion

Synthesis of Racemic β -Fluoroalkyl- β -Amino Acids 5a-f. Recently, we have developed a general method for synthesis of racemic β -fluoroalkyl- β -amino acids starting from readily available ketoesters **1a-f** and benzylamine (Scheme 1).⁹ Two sequential base-catalyzed [1,3]-proton transfers lead to facile conversions of enamines **2a-f** into the *N*-benzylidene derivatives of β -amino acids **4a-f** which were deprotected by an acidic hydrolysis to give free amino acids **5a-f** in good overall yield. Following this procedure all starting amino acids **5a-f** were prepared on a multi-gram scale and were used for further transformation after isolation by cation exchange resin without additional purification.

Synthesis of Racemic *N*-Phenylacetyl- β -Fluoroalkyl- β -Amino Acids 6a-f.

From the viewpoint of synthetic convenience and reagent availability the procedure of Schotten and Baumann for the acylation of amino acids was regarded as the most attractive for the preparation of *N*-phenylacetyl derivatives **6a-f**. However, previously we have shown that the presence of trifluoromethyl group in the α -position of α -amino carboxylic acids strongly influences on the amino function decreasing its reactivity in acylation reactions.¹⁰ Thus, the pK(NH₂) value of β -trifluoromethyl- β -alanine (**5a**) was found to be 6.3 which is substantially lower than that for fluorine-free β -amino acids.⁵ Nevertheless, as experiments revealed, treatment of water-acetone solutions of β -amino acids **5a-f** in the presence of potassium bicarbonate with phenylacetyl chloride at low temperature (-5 °C) provide the desired *N*-phenylacetyl derivatives **6a-f** with good-to-excellent (73-98%) isolated yields (Scheme 2). Analytically pure samples of **6a-f** for biocatalytic resolution were obtained by single recrystallizations of crude *N*-phenylacetyl derivatives **6a-f** from toluene.

Scheme 2



Reagents and Conditions: *i*, water/acetone (1/1), KHCO_3 , phenylacetyl chloride, -5°C , 2 hr., then room temp., 1 h; *ii*, penicillin acylase, $22\text{--}25^\circ\text{C}$, pH 7.4–7.6; *iii*, 6 N HCl, 70°C , 11 hr.

Biocatalytic Resolution of *N*-Phenylacetyl- β -Fluoroalkyl- β -Amino Acids 6a-f. Due to the low $\text{pK}(\text{NH}_2)$ values of β -fluoroalkyl- β -amino acids 5a-f it was impossible to use the common spectrophotometric *o*-phthalaldehyde method¹¹ to determine the concentration of biocatalytically produced amino acid. For instance, to achieve a value of the molar extinction coefficient as high as $2070\text{ M}^{-1}\text{ cm}^{-1}$, the reaction mixture was kept for 3 h at 70°C . So, this method is too time consuming and not sensitive enough to follow the time dependence of β -fluoroalkyl- β -amino acids concentration. Instead, we took advantage of the fact, that at pH 7.5 the amino group of β -fluoroalkyl- β -amino acid is fully protonated, and used continuous automatic titration (pH-stat) at the constant pH (7.5) to follow the rate of enzymatic reaction. The course of the biocatalytic hydrolysis was monitored by consumption of 20% NH_4OH and was stopped by acidification of reaction mixture with 2 N HCl at an appropriate point to obtain 50% conversion of starting material. The reaction rate slowed down significantly or even stopped when a conversion of 50% was reached. Regarding the reactivity, it is worth noting, that the rate of penicillin acylase-catalyzed hydrolytic reaction decreased with an increase in the length of the fluoroalkyl chain in the *N*-phenylacetyl derivatives 6a-f. Thus, a reaction time for 50% conversion varied from 4.5 hr. for 6a to about 48 hr. for 6f. However, the enantioselectivity of the biocatalytic process was practically uninfluenced by the nature of fluoroalkyl chain. Chiral HPLC analysis¹² of crude amino acids 7a-f, released by the enzyme and isolated by means of cation exchange resin Dowex-50, has shown that their enantiomeric purities are, at least (the sensitivity limit of the method), 95% ee. The enzymatically unconverted *N*-phenylacetyl derivatives 8a-f were isolated from the water solutions by extraction with ethyl acetate (see experimental part) and without purification were hydrolyzed by 6 N HCl to give after dehydrochlorination with cation exchange resin Dowex-50 free amino acids 9a-d, which enantiomeric purity, according to HPLC analysis, is more than 90% ee.

These results show the high reactivity and enantioselectivity of the penicillin acylase on *N*-phenylacetyl derivatives **6a-f**. Preliminary experiments on the ratio of the second-order rate constants of the enzyme-catalyzed hydrolysis of (*R*)- and (*S*)-*N*-phenylacetyl derivative of β -trifluoromethyl- β -alanine has revealed that the enzyme stereoselectivity is 500, i.e. $(k_{cat}/K_M)_R/(k_{cat}/K_M)_S = 500$.

Determination of Absolute Configuration of β -Fluoroalkyl- β -Amino Acids. Since it is well known that penicillin acylase does not cleave (*D*)- α -amino carboxylic¹³ or α -amino alkylphosphonic acids¹⁴, as well as (*D*)-enantiomers of fluorine-free β -amino^{8a,15} and γ -amino acids,¹⁶ we expected that our biocatalytically prepared β -fluoroalkyl- β -amino acids would be members of the (*L*)-series. We have confirmed this for the (*R*)- β -trifluoromethyl- β -alanine (**7a**) with X-ray analysis.^{8b} Taking into account that the sense of enantioselection during the enzymatic hydrolysis¹³ should be the same for all *N*-phenylacetyl derivatives **6a-f** and the fact of similarity in the order of elution in conditions of chiral HPLC analysis of biocatalytically reactive enantiomers and enzymatically unreactive ones (Table 1), we can attribute (*R*)-absolute configuration for all biocatalytically prepared amino acids **7a-f** and (*S*)-absolute configuration for enantiomers **9a-d** obtained by chemical hydrolysis of *N*-phenylacetyl derivatives **8a-f**.

Table 1. Chromatographic Behavior of β -Fluoroalkyl- β -Amino Acids

Entry	β -amino acid	Retention Times of Enantiomers (min) ^a	
		(<i>R</i>)	(<i>S</i>)
1	CF ₃ -CH(NH ₂)-CH ₂ COOH	5.8	6.7
2	C ₂ F ₅ -CH(NH ₂)-CH ₂ COOH	11.7	13.1
3	C ₃ F ₇ -CH(NH ₂)-CH ₂ COOH	18.5	22.1
4	CHF ₂ -CH(NH ₂)-CH ₂ COOH	5.6	5.9
5	H(CF ₂) ₂ -CH(NH ₂)-CH ₂ COOH	8.0	9.0
6	H(CF ₂) ₄ -CH(NH ₂)-CH ₂ COOH	13.4	15.9

^a Column: Nucleosil Chiral [(*L*)-Hydroxy-Pro] - (250 x 4.0 mm), Macherey-Nagel, Germany. The mobile phase: 5.0 mM copper sulfate solutions at a flow-rate of 0.5 ml/min.

CONCLUSIONS

We have disclosed that some β -fluoroalkyl- β -amino acids can be obtained in enantiomerically pure form in good yield by penicillin acylase-catalyzed resolution of their racemic *N*-phenylacetyl derivatives. The results obtained revealed a significant decrease in reaction rate of enzymatic hydrolysis with increasing a length of fluoroalkyl group, whereas the enantiodifferentiation remains very high and almost constant with a change in the size of fluoroalkyl chain and so it possesses no limitation on the generality of the method in view of optical purity of desired amino acids. Taking into account that this method employs an inexpensive, commercially available enzyme and cheap readily accessible starting racemic material, it could be practically useful for production of enantiomerically pure β -fluoroalkyl- β -amino acids on a preparative scale.

ACKNOWLEDGMENT

We thank the Ukrainian Academy of Sciences and the JSPS Foundation (Japan) for financial support.

EXPERIMENTAL

General. $^1\text{H-NMR}$ was performed on a Varian VXR-300 (299.94 MHz) or Gemini-200 (199.98 MHz) spectrometer. $^{19}\text{F-NMR}$ spectra were recorded on Bruker WP-200 (188.98 MHz). Tetramethylsilane and CFCl_3 were used as internal standards in organic solvents and sealed in a glass capillary for D_2O solutions. NMR data are reported in δ units. HPLC analyses were performed on LKB (Sweden) liquid chromatographic system consisting of a model 2150 HPLC pump, a model 7410 injector, a model 2140 detector, a model 2200 recording integrator and model 2155 column oven. Chiral stationary phase column Nucleosil Chiral [(*L*)-Hydroxy-Pro] - (250 x 4.0 mm), Macherey-Nagel, Germany. Eluent: 5.0 mM CuSO_4 , flow-rate 0.5 mL/min, 35 °C, detection at 235 nm. Optical rotations were measured using a Perkin-Elmer 241 polarimeter. Determination of the β -trifluoromethyl- β -alanine amino group pK value was performed on RTS-622 automatic titration system (Radiometer, Copenhagen, Denmark) using a stepped titration curve technique described in RTS-622 Operating Instructions.

Melting points (mp) are uncorrected and were obtained on a capillary apparatus.

Penicillin acylase (EC 3.5.1.11) from *E. coli* was used in soluble form.¹⁴

General procedure for the synthesis of racemic *N*-phenylacetyl derivatives 6a-f. Phenylacetyl chloride (0.21 mol) in acetone (70 mL) was added to the solution of racemic β -amino acid (0.13 mol) and potassium bicarbonate (0.356 mol) in aqueous acetone (1/1, 600 mL) under stirring at -5 °C. The resulted solution was stirred for 2 h at -5 °C and 1 h at room temperature. The reaction mixture was filtered, acetone evaporated and washed with diethyl ether (3 x 50 mL). The aqueous phase was acidified with 2N HCl up to pH 2.0 and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were dried with MgSO_4 and concentrated. The residue was subjected to recrystallization from toluene.

***rac*-4,4,4-Trifluoro-3-(*N*-Phenylacetylamino)butanoic acid (6a):** 85%, mp144-146 °C; $^1\text{H-NMR}$ (CD_3SOCD_3): 2.66, 2.86 (ABX, $J_{\text{AB}} = 16.4$ Hz, $J_{\text{AX}} = 9.1$, $J_{\text{BX}} = 4.6$ Hz, 2H, CH_2), 3.57 (s, 2H, $\text{CH}_2\text{C}_6\text{H}_5$), 5.11 (dddq, $J_{\text{HH}} = 9.1$ Hz, $J_{\text{HH}} = 4.6$ Hz, $J_{\text{HH}} = 8.4$ Hz, $J_{\text{HF}} = 7.5$ Hz, 1H, CH), 7.27 (m, 5H, C_6H_5), 7.80 (d, $J_{\text{HH}} = 8.4$ Hz, 1H, NH). Anal. Calcd for $\text{C}_{12}\text{H}_{12}\text{F}_3\text{NO}_3$: C, 52.37; H, 4.40; F, 20.71. Found: C, 52.34; H, 4.38; F, 20.77.

***rac*-5,5,5,4,4-Pentafluoro-3-(*N*-Phenylacetylamino)pentanoic acid (6b):** 77%, mp155-156 °C; $^1\text{H-NMR}$ (CD_3COCD_3): 2.67, 2.91 (ABX, $J_{\text{AB}} = 16.2$ Hz, $J_{\text{AX}} = 8.7$, $J_{\text{BX}} = 4.5$ Hz, 2H, CH_2), 3.63 (s, 2H, $\text{CH}_2\text{C}_6\text{H}_5$), 5.26 (m, 1H, CH), 7.23-7.40 (m, 5H, C_6H_5), 7.80 (m, 1H, NH). Anal. Calcd for $\text{C}_{13}\text{H}_{12}\text{F}_5\text{NO}_3$: C, 48.00; H, 3.72; F, 29.21. Found: C, 48.17; H, 3.75; F, 29.00.

***rac*-6,6,6,5,5,4,4-Heptafluoro-3-(*N*-Phenylacetylamino)hexanoic acid (6c):** 80%, mp163-164 °C; $^1\text{H-NMR}$ (CD_3COCD_3): 2.64, 2.80 (ABX, $J_{\text{AB}} = 15.6$ Hz, $J_{\text{AX}} = 8.7$, $J_{\text{BX}} = 4.8$ Hz, 2H, CH_2), 3.64 (s, 2H, $\text{CH}_2\text{C}_6\text{H}_5$), 5.30 (m, 1H, CH), 7.25-7.35 (m, 5H, C_6H_5), 7.80 (m, 1H, NH). Anal. Calcd for $\text{C}_{14}\text{H}_{12}\text{F}_7\text{NO}_3$: C, 44.81; H, 3.22; F, 35.44. Found: C, 45.02; H, 3.31; F, 35.37.

***rac*-4,4-Difluoro-3-(*N*-Phenylacetylamino)butanoic acid (6d):** 98%, mp163-165 °C; $^1\text{H-NMR}$ (CDCl_3): 2.69, 2.75 (ABX, $J_{\text{AB}} = 16.8$ Hz, $J_{\text{AX}} = 9.0$, $J_{\text{BX}} = 4.5$ Hz, 2H, CH_2), 3.56 (s, 2H, $\text{CH}_2\text{C}_6\text{H}_5$), 4.25 (m, 1H, CH), 5.03 (td, $J_{\text{HF}} = 56.1$ Hz, $J_{\text{HH}} = 3.0$, 1H, CHF_2), 7.26-7.30 (m, 5H, C_6H_5),

7.55 (m, 1H, NH). Anal. Calcd for $C_{12}H_{13}F_2NO_3$: C, 56.03; H, 5.09; F, 14.77. Found: C, 56.01; H, 5.03; F, 14.75.

***rac*-5,5,4,4-Tetrafluoro-3-(*N*-Phenylacetyl-amino)pentanoic acid (6e):** 83%, mp 125-128 °C; 1H -NMR (CD_3COCD_3): 2.63, 2.88 (ABX, $J_{AB} = 14.4$ Hz, $J_{AX} = 9.3$, $J_{BX} = 5.4$ Hz, 2H, CH_2), 3.57 (s, 2H, $CH_2C_6H_5$), 5.20 (m, 1H, CH), 6.18 (tdd, $J_{HF} = 52.3$ Hz, $J_{HF} = 3.3$ Hz, $J_{HF} = 8.1$ Hz, 1H, CHF_2), 7.30-7.35 (m, 5H, C_6H_5), 7.78 (d, $J_{HH} = 8.8$ Hz, 1H, NH). Anal. Calcd for $C_{13}H_{13}F_4NO_3$: C, 50.82; H, 4.26; F, 24.74. Found: C, 50.95; H, 4.38; F, 24.77.

***rac*-7,7,6,6,5,5,4,4-Octafluoro-3-(*N*-Phenylacetyl-amino)heptanoic acid (6f):** 73%, mp 135-138 °C; 1H -NMR (CD_3COCD_3): 2.67, 2.90 (ABX, $J_{AB} = 16.5$ Hz, $J_{AX} = 9.0$, $J_{BX} = 4.8$ Hz, 2H, CH_2), 3.58 (s, 2H, $CH_2C_6H_5$), 5.42 (m, 1H, CH), 6.69 (tt, $J_{HF} = 51.0$ Hz, $J_{HF} = 5.4$ Hz, 1H, CHF_2), 7.25-7.40 (m, 5H, C_6H_5), 7.82 (m, 1H, NH). Anal. Calcd for $C_{15}H_{13}F_8NO_3$: C, 44.23; H, 3.22. Found: C, 44.42; H, 3.37.

Typical procedure for the enzymatic hydrolysis of *rac*-*N*-phenylacetyl derivatives 6a-f.

(*R*)-4,4,4-Trifluoro-3-aminobutanoic acid (7a). The pH of the solution of 30 g (0.11 mol) of *N*-phenylacetyl derivative 6a in water (500 mL) was adjusted with 20 % NH_4OH to 7.5 and 15 mL of 10^{-6} M penicillin acylase solution was added. The mixture was stirred at 22-25 °C, and pH was constantly adjusted in the limits of 7.4-7.6 by dropwise addition of 20 % NH_4OH . On the reaching of 50% conversion of starting material the reaction mixture was acidified by 2 N HCl up to pH 2.0 and extracted with ethyl acetate (3 x 100 mL). The aqueous phase was evaporated in vacuum (50 °C, 30-40 mm Hg). Dowex-50 (H^+ -form) column chromatography yielded 7.4 g (86%) of (+)-(*R*)-7a, after recrystallization from methanol mp 173-174 °C; $[\alpha]_D^{25} = +27.6$, $[\alpha]_{578}^{25} = +28.5$, $[\alpha]_{546}^{25} = +32.4$, $[\alpha]_{436}^{25} = +53.2$, $[\alpha]_{365}^{25} = +72.6$ (c 2.6 g N HCl). 1H -NMR (CD_3SOCD_3): 2.78, 3.01 (ABX, $J_{AB} = 17.8$ Hz, $J_{AX} = 8.8$ Hz, $J_{BX} = 4.2$ Hz, 2H, CH_2), 4.39 (qdd, $J = 8.8$ Hz, $J = 4.2$ Hz, $J = 10.8$ Hz, 1H, CH). Anal. Calcd for $C_4H_6F_3NO_2$: C, 30.58; H, 3.85; F, 36.28; N, 8.92. Found: C, 30.42; H, 3.91; F 36.13; N, 8.96.

(*S*)-4,4,4-Trifluoro-3-aminobutanoic acid (9a). The ethyl acetate extracts, obtained after *rac*-*N*-phenylacetyl derivative 6a enzymatic hydrolysis, were combined, dried with $MgSO_4$ and evaporated. The recrystallization of the residue from toluene yielded 12.3 g (82%) of (*S*)-8a; mp 163-166 °C, $[\alpha]_D^{25} = +4.6$ (c 1.0 CH_3COCH_3). The 1H -NMR spectrum of (*S*)-8a is identical to that of *rac*-6a. 1.8 g (6.5 mmol) of (*S*)-8a was dissolved in 6 N HCl (30 mL) and heated at 70 °C for 11 hr. The reaction mixture was evaporated in vacuum (50 °C, 30-40 mm Hg) to dryness. The residue was dissolved in water (50 mL) and washed with ethyl acetate (3 x 20 mL). Free (-)-(*S*)-9a was isolated from the aqueous phase using Dowex-50 column chromatography. The yield was 0.91 g (88.6%), after recrystallization from methanol, mp 170-173 °C; $[\alpha]_D^{25} = -27.1$, $[\alpha]_{578}^{25} = -28.2$, $[\alpha]_{546}^{25} = -31.4$, $[\alpha]_{436}^{25} = -52.6$, $[\alpha]_{365}^{25} = -79.2$ (c 1.4 g N HCl). The 1H -NMR spectrum of (-)-(*S*)-9a is identical to that of (+)-(*R*)-7a.

The other biocatalytic resolutions were done in the same way. (*S*)-Amino acids 9b-d were prepared from crude enzymatically unreactive *N*-phenylacetyl derivatives 8b-d which structure and chemical purity were controlled by 1H NMR analysis. 1H NMR Spectra of 8b-d are similar to racemic patterns.

(*R*)-5,5,5,4,4-Pentafluoro-3-aminopentanoic acid (7b): 82%, mp 135-140 °C (decomp.) from H_2O . $[\alpha]_D^{22} = +37.1$ (c 0.3 H_2O). 1H -NMR (0.1 N DCl in D_2O): 2.75, 2.97 (ABX, $J_{AB} = 18.2$ Hz, $J_{AX} = 9.2$ Hz, $J_{BX} = 4.0$ Hz, 2H, CH_2), 4.46 (qdd, $J = 9.2$ Hz, $J = 4.2$ Hz, $J = 12.8$ Hz, 1H, CH). ^{19}F -NMR

(D₂O): -83.8 (s, 3F, CF₃), -121.5, -125.5 (AB, J_{AB} = 256 Hz, 2F, CF₂). Anal. Calcd for C₅H₆F₅NO₂: C, 28.99; H, 2.92; F, 45.87; N, 6.76. Found: C, 29.13; H, 2.98; F, 45.64; N, 6.86.

(*S*)-**5,5,5,4,4-Pentafluoro-3-aminopentanoic acid (9b)**: 73%, mp 133-137 °C (decomp.) from H₂O. $[\alpha]_{\text{D}}^{22} = -36.7$ (c 0.1 H₂O). The ¹H-NMR spectrum of (-)-(*S*)-**9b** is identical to that of (+)-(*R*)-**7b**.

(*R*)-**6,6,6,5,5,4,4-Heptafluoro-3-aminohexanoic acid (7c)**: 80%, mp 155-157 °C (decomp.) from H₂O. $[\alpha]_{\text{D}}^{22} = +27.0$ (c 0.1 H₂O). ¹H-NMR (0.1 N DCl in D₂O): 2.76, 2.99 (ABX, J_{AB} = 18.0 Hz, J_{AX} = 9.3 Hz, J_{BX} = 3.3 Hz, 2H, CH₂), 4.50 (m, 1H, CH). Anal. Calcd for C₆H₆F₇NO₂: C, 28.03; H, 2.35. Found: C, 28.31; H, 2.33.

(*S*)-**6,6,6,5,5,4,4-Heptafluoro-3-aminohexanoic acid (9c)**: 61%, mp 153-156 °C (decomp.) from H₂O. $[\alpha]_{\text{D}}^{22} = -26.1$ (c 0.05 H₂O). The ¹H-NMR spectrum of (-)-(*S*)-**9c** is identical to that of (+)-(*R*)-**7c**.

(*R*)-**4,4-Difluoro-3-aminobutanoic acid (7d)**: 88%, mp 200-203 °C (decomp.) from H₂O. $[\alpha]_{\text{D}}^{25} = +19.5$ (c 0.2 H₂O). ¹H-NMR (D₂O): 2.20, 2.39 (ABX, J_{AB} = 16.2 Hz, J_{AX} = 9.0 Hz, J_{BX} = 4.8 Hz, 2H, CH₂), 3.28 (m, 1H, CH), 5.86 (td, $J_{\text{HF}} = 56.7$ Hz, $J_{\text{HH}} = 3.6$ Hz, 1H, CHF₂). ¹⁹F-NMR (D₂O): -127.5 (d, $J = 56.7$ Hz, CHF₂). Anal. Calcd for C₄H₇F₂NO₂: C, 34.54; H, 5.07; F, 27.32; N, 10.07. Found: C, 34.57; H, 5.12; F, 27.28; N, 10.11.

(*S*)-**4,4-Difluoro-3-aminobutanoic acid (9d)**: 72%, mp 201-203 °C (decomp.) from H₂O. $[\alpha]_{\text{D}}^{25} = -17.5$ (c 0.06 H₂O). The ¹H-NMR spectrum of (-)-(*S*)-**9d** is identical to that of (+)-(*R*)-**7d**.

(*R*)-**5,5,4,4-Tetrafluoro-3-aminopentanoic acid (7e)**: 74%, mp 126 °C (decomp.) from H₂O. $[\alpha]_{\text{D}}^{22} = +23.2$ (c 0.4 MeOH). ¹H-NMR (CD₃OD): 2.40-3.00 (m, 2H, CH₂), 4.53 (m, 1H, CH), 6.11 (tdd, $J_{\text{HF}} = 53.0$ Hz, $J_{\text{HF}} = 7.5$ Hz, $J_{\text{HF}} = 4.2$ Hz, 1H, CHF₂). Anal. Calcd for C₅H₇F₄NO₂: C, 31.75; H, 3.73; F, 40.19; N, 7.41. Found: C, 31.64; H, 3.69; F, 40.25; N, 7.34.

(*R*)-**7,7,6,6,5,5,4,4-Octafluoro-3-aminoheptanoic acid (7f)**: 63%, mp 138-140 °C (decomp.) from H₂O. $[\alpha]_{\text{D}}^{22} = +12.2$ (c 0.1 MeOH). ¹H-NMR (CD₃OD): 2.80, 3.15 (ABX, J_{AB} = 18.1 Hz, J_{AX} = 8.4 Hz, J_{BX} = 4.2 Hz, 2H, CH₂), 4.66 (m, 1H, CH), 6.69 (tt, $^2J_{\text{HF}} = 51.0$ Hz, $^3J_{\text{HF}} = 5.4$ Hz, 1H, CHF₂). Anal. Calcd for C₇H₇F₈NO₂: C, 29.08; H, 2.44. Found: C, 29.13; H, 2.49.

REFERENCES AND NOTES

- 1 Permanent address: Institute of Bioorganic Chemistry and Petrochemistry of the Ukrainian Academy of Sciences, Kiev 253160, Ukraine.
- 2 For reviews: (a) Welch, J. T.; Eswarakrischnan, S. *Fluorine in Bioorganic Chemistry*, J. Wiley and Sons, New York, 1991. (b) *Selective Fluorination in Organic and Bioorganic Chemistry*, Welch, J. T., Ed.; American Chemical Society: Washington, 1991. (c) *Biomedical Aspects of Fluorine Chemistry*, Filler, R.; Kobayashi, Y., Eds.; Kodansha LTD: Tokyo, Elsevier Biomedical Press: Amsterdam - New York - Oxford, 1982. (d) Sieler, M.; Jung, M. J.; Koch-Waser, *Enzyme-Activated Irreversible Inhibitors*, Elsevier, Amsterdam, 1988. (e) Welch, J. T. *Tetrahedron* 1987, 43, 3123. (f) Bravo, P.; Resnati, G. *Tetrahedron Asymmetry* 1990, 1, 661. (g) Resnati, G. *Tetrahedron* 1993, 49, 9385.
- 3 For reviews: (a) Seebach, D. *Angev. Chem. Int. Ed. Engl.* 1990, 29, 1320. (b) Kukhar', V. P.; Soloshonok, V. A. *Russ. Chem. Rev. Engl.* 1991, 60, 850. (c) Kukhar', V. P.; Svistunova, N. Yu.; Soloshonok, V. A.; Solodenko, V. A. *Russ. Chem. Rev. Engl.* 1993, 62, 284. (d) *Fluorine-Containing Amino Acids*, Kukhar, V. P.; Soloshonok, V. A., Eds.; John Wiley and Sons Publisher, scheduled to appear in 1994.

- 4 (a) Araki, K.; Wichtowski, J. A.; Welch, J.T. *Tetrahedron Lett.* 1991, 32, 5461. (b) Kaweck, R.; Welch, J. T. *Tetrahedron Lett.* 1993, 34, 3087. (c) Welch, J.T.; Araki, K.; Kaweck, R.; Wichtowski, J. A. *J. Org. Chem.* 1993, 58, 2454.
- 5 (a) Drey, C. N. C. In *Chemistry and Biochemistry of the Amino Acids*; Weinstein, B., Ed.; Dekker, New York, 1976, 4, 241. (b) Drey, C. N. C. In *Chemistry and Biochemistry of the Amino Acids*; Barrett, G. C., Ed.; Chapman and Hall: New York, 1985; Chapter 3. (c) Spatola, A. F. In *Chemistry and Biochemistry of the Acids, Peptides and Proteins*; Weinstein, B., Ed.; Marcel Dekker: New York, 1983; Vol. 7, pp 331.
- 6 (a) Davies, S. G.; Ichihara, O. *Tetrahedron Asymmetry* 1991, 2, 183. (b) Konopelski, K. P.; Chu, K. S.; Negrete, G. R. *J. Org. Chem.* 1991, 56, 1355. (c) Noyori, R.; Lubell, W. D.; Kitamura, M. *Tetrahedron Asymmetry* 1991, 2, 543. (d) Corey, E. J.; Decicco, C. P.; Newbold, R. C. *Tetrahedron Lett.* 1991, 32, 5287. (e) Bringmann, G.; Geuder, T. *Synthesis* 1991, 829. (f) Andres, C.; Gonzalez, A.; Pedraa, R.; Perez-Encabo, A. *Tetrahedron Lett.* 1992, 33, 2895. (g) Hawkins, J. M.; Lewis, T. A. *J. Org. Chem.* 1992, 57, 2114. (h) Juaristi, E.; Escalante, J.; Lamatsch, B.; Seebach, D. *J. Org. Chem.* 1992, 57, 2396. (i) Davis, F. A.; Reddy, R. T.; Reddy, R. E. *J. Org. Chem.* 1992, 57, 6387. (j) Yamamoto, H.; Hattori, K.; Miyata, M. *J. Am. Chem. Soc.* 1993, 115, 1151. (k) Enders, D.; Klatt, M.; Funk, R. *Synlett*, 1993, 226. (l) Davies, S. G.; Ichihara, O.; Garrido, N. M.; Walters, I. A. S. *J. Chem. Soc. Chem. Commun.* 1993, 1153. (m) Davies, S. G.; Ichihara, O.; Walters, I. A. S. *Synlett*, 1993, 461. (n) Rico, J. G.; Lindmark, R. J.; Rogers, T. E.; Bovy, Ph. R. *J. Org. Chem.* 1993, 58, 7948. (o) Burgess, K.; Liu, L. T.; Pal, B. *J. Org. Chem.* 1993, 58, 4758. (p) Bates, R. B.; Gangwar, S. *Tetrahedron Asymmetry*, 1993, 4, 69. (r) Hawkins, J. M.; Lewis, T. A. *J. Org. Chem.* 1994, 59, 649.
- 7 Soloshonok, V. A.; Kirilenko, A. G.; Galushko, S. V.; Kukhar, V. P. *Tetrahedron Lett.* submitted.
- 8 (a) Soloshonok, V. A.; Švedas, V. K.; Kukhar, V. P.; Kirilenko, A. G.; Rybakova, A. V.; Solodenko, V. A.; Fokina, N. A.; Kogut, O. V.; Galaev, I. Yu.; Kozlova, E. V.; Shishkina, I. P.; Galushko, S. V. *Synlett* 1993, 339. (b) Kukhar, V. P.; Soloshonok, V. A.; Švedas, V. K.; Kotik, N. V.; Galaev, I. Yu.; Kirilenko, A. G.; Kozlova, E. V. *Bioorgan. Chem. (Russ.)* 1993, 19, 474.
- 9 Soloshonok, V. A.; Kirilenko, A. G.; Kukhar, V. P.; Resnati, G. *Tetrahedron Lett.* 1993, 34, 3621.
- 10 Kobzev, S. P.; Soloshonok, V.A.; Galushko, S. V.; Yagupolskii, Yu. L.; Kukhar, V. P. *J. Gen. Chem. USSR* 1989, 59, 801.
- 11 Švedas, V.-J. K.; Galaev, I. Y.; Borisov, I. L.; Berezin, I. V. *Analytical Biochem.* 1980, 101, 188.
- 12 Galushko, S.V.; Shishkina, I. P.; Soloshonok, V. A. *J. Chromatog.* 1992, 592, 345.
- 13 (a) Cole, M. *Nature* 1964, 203, 519. (b) Margolin, A. L.; Švedas, V. K.; Berezin, I. V. *Biochim. Biophys. Acta*, 1980, 616, 283.
- 14 Solodenko, V. A.; Kasheva, T. N.; Kukhar, V. P.; Kozlova, E. V.; Mironenko, D. A.; Švedas, V. K. *Tetrahedron*, 1991, 47, 3989.
- 15 Rossi, D.; Lucente, G.; Romeo, A. *Experientia*, 1977, 33, 1557.
- 16 Margolin, A. L. *Tetrahedron Lett.* 1993, 34, 1239.

(Received 4 April 1994)